Iterum <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Extension and Increased Interest Rate on Promissory Note with Pfizer
Iterum Therapeutics plc, a company dedicated to developing next-generation antibiotics, announced an extension of the term of their $20 million promissory note owed to Pfizer Inc. The due date for this regulatory milestone payment, associated with the FDA approval of ORLYNVAH™, has been extended from October 2026 to October 2029. In connection with this extension, the annual interest rate on the note will increase from 8% to 10% starting in October 2026. This extension allows Iterum to strategically invest capital from ORLYNVAH™ sales to support its market launch and expansion efforts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-073950), on May 19, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。